Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 9;60(33):17963-17968.
doi: 10.1002/anie.202106458. Epub 2021 Jul 12.

Amphiphilic Iodine(III) Reagents for the Lipophilization of Peptides in Water

Abhaya Kumar Mishra  1 , Romain Tessier  1   2 , Durga Prasad Hari  1 , Jerome Waser  1
Affiliations

Amphiphilic Iodine(III) Reagents for the Lipophilization of Peptides in Water

Abhaya Kumar Mishra et al. Angew Chem Int Ed Engl. .

Abstract

We report the functionalization of cysteine residues with lipophilic alkynes bearing a silyl group or an alkyl chain using amphiphilic ethynylbenziodoxolone reagents (EBXs). The reactions were carried out in buffer (pH 6 to 9), without organic co-solvent or removal of oxygen, either at 37 °C or room temperature. The transformation led to a significant increase of peptide lipophilicity and worked for aromatic thiols, homocysteine, cysteine, and peptides containing 4 to 18 amino acids. His6 -Cys-Ubiquitin was also alkynylated under physiological conditions. Under acidic conditions, the thioalkynes were converted into thioesters, which could be cleaved in the presence of hydroxylamine.

Keywords: amphiphilic reagents; hypervalent iodine; lipidation; lipopeptide; ubiquitin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
a) Chemical methods for stable natural lipidation. b) Reported reagents for non‐natural lipidation. c) EBX reagents for cysteine labeling. d) This work: amphiphilic reagents for non‐natural lipidation under physiological conditions. DMPA=2,2‐dimethoxy‐2‐phenylacetophenone, NMP=N‐methyl‐2‐pyrrolidone, BIPHEPHOS=6,6′‐[(3,3′‐di‐tert‐butyl‐5,5′‐dimethoxy‐1,1′‐biphenyl‐2,2′‐diyl)bis(oxy)]bis(di‐benzo[d,f][1,3,2]dioxaphosphepin), TIPS=triisopropylsilyl, TMS=trimethylsilyl.
Scheme 1
Scheme 1
Synthesis of TIPS‐EBX‐SO3M (4 a) and C14H29‐EBX‐SO3M (4 b). a) NaIO4 (1.05 equiv), 30 % aq. AcOH (v/v), reflux, 4 h; b) TMSOTf (3.0 equiv), pyridine (6.0 equiv), DCE, 40 °C, 22 h; c) BF3⋅Et2O (3.0 equiv), pyridine (1.1 equiv), CH3CN, rt, 24 h.
Scheme 2
Scheme 2
Optimized conditions for the reaction of 4 b with glutathione (6). HPLC‐MS yield is indicated. [a] Isolated yield. [b] Calibrated yield.
Scheme 3
Scheme 3
Scope of the alkynylation reaction for a) non‐peptides, b) tetra‐ and hexa‐peptides and c) larger peptides. All the reactions were performed in 0.5 to 64.0 μmol scale at 10 mM concentration. Freshly prepared buffer was used without removing oxygen. Yields: relative ratio based on reverse phase HPLC‐MS chromatogram unless stated otherwise. [a] Isolated yield. [b] Reactions were performed in 100 mM PB buffer at pH 8.0 at rt. [c] Calibrated yield.
Scheme 4
Scheme 4
Alkynylation of peptides 22–24 and His6‐Cys‐ubiquitin (25). Reaction conditions: for 22 a and 23 a: 4 a (1.5 equiv), 10 mM Tris pH 7.4, 37 °C, for 22 b and 23 b: 4 b (1.2 equiv), 200 mM Tris buffer pH 8.0, rt. [a] Isolated yield. [b] Calibrated yield. [c] 4 equiv and [d] 6 equiv of 4 a was used in 10 mM Tris pH 7.4 at 37 °C, 5 mM. [e] Reaction was performed at 300 μM concentration.
Scheme 5
Scheme 5
a) Access to thioesters from unprotected peptides in one pot via thioalkynes and b) Cleavage of the thioesters. See Supporting Information for detailed reaction conditions. [a] VBXs remain untouched under these reaction conditions. [b] Isolated yield. [c] Calibrated yield.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Quianzon C. C., Cheikh I., J. Community Hosp. Intern. Med. Perspect. 2012, 2, 10.3402/jchimp.v2i2.18701. - DOI - PMC - PubMed
    1. None
    1. Castanho M., Santos N. C., Peptide Drug Discovery and Development, Wiley-VCH, Weinheim, 2011;
    1. Craik D. J., Fairlie D. P., Liras S., Price D., Chem. Biol. Drug Des. 2013, 81, 136; - PubMed
    1. Dunn B. M., Peptide Chemistry and Drug Design, Wiley, Hoboken, 2015;

Publication types

LinkOut - more resources